Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Infectious Disease

Articles with lock require a GLG News subscription
Posted December 11, 2006
Finally - a head to head study.
Analysis of: Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Shows 100% Seroprotection Regardless of Vaccination Schedule in Phase 2 Trial | www.pipelinereview.com
Author: GLG Member Program Contributor
The data is impressive - the clinical strategy is bold. Going head to head with the market leader is risky, but if it pans out, the potential is enormous.
Posted December 11, 2006
Universal use of Zostavax is a fantasy
Analysis of: FDA approves Zostavax, Merck's new vaccine for preventing shingles in adults 60 and older | www.therapeuticsdaily.com
Author: GLG Member Program Contributor
-Zostavax is being touted as a "homer" by some in this thread. Although clearly beneficial, other more important vaccines that are supposedly "universal" are already routinely not given to a large fraction of the elderly.-Vaccines for special populations are only as universal as the care that delivers...
Posted December 11, 2006
Numax is effective, but at what price?
Analysis of: Numax(R) Achieves Primary Endpoint In Preliminary Analysis of Data From Comparative Phase 3 Trial With Synagis(R) | biz.yahoo.com
Author: GLG Member Program Contributor
-Numax, if approved, is certain to be more expensive than its parent compound Synagis.-Synagis already works extremely well and is extremely expensive. The only reason for development of Numax is patent protection and higher margin. This may be a reason in and of itself for the FDA to decline to approve...
Posted December 11, 2006
Once daily amoxicillin equivalent to penicillin given 4 times daily in curing tonsillitis/pharyngitis
Analysis of: Advancis Pharmaceutical Reports Positive Results for Amoxicillin PULSYS Phase III Trial | www.advancispharm.com
Author: GLG Member Program Contributor
A double blind, double dummy randomized parallel group trial compared once daily amoxicillin PULSYS 775 mg versus penicillin 250 mg four times daily for 10 days in the treatment of streptococcal pharyngitis and tonsillitis. The trial involved 620 adults and adolescents in 50 centers. The bacteriologic...
Posted December 4, 2006
Non inferiority is not the answer
Analysis of: Arpida reveals positive results... | www.nasdaq.com
Author: GLG Member Program Contributor
The results of this study do not show us a better drug. We could use a cidal drug that has an oral equivalent  
Posted December 1, 2006
Iclaprim will not fill a void in MRSA market.
Analysis of: Arpida reveals positive results... | www.nasdaq.com
Author: GLG Member Program Contributor
Iclaprim is a new injectable antibiotic with anti-MRSA activity.Iclaprim was not superior to Linezolid for treatment of skin and skin-tissue MRSA infections, but was not tested for pulmonary and invasive infections.
Posted December 1, 2006
Iclaprim for MRSA
Analysis of: Arpida reveals positive results... | www.nasdaq.com
Author: GLG Member Program Contributor
1. Iclaprim is a new antibiotic with activity against MRSA.2. Iclaprim was compared to Linezolid for treatment of complicated skin and skin-structure infections. 
Posted November 27, 2006
Tamiflu and neurological issues
Analysis of: Tamiflu to carry warning about abnormal behaviour | www.news-medical.net
Author: GLG Member Program Contributor
1. Most reports are in Japanese children2. Influenza itself may lead to neurologic issues/abnormal behavior
Posted November 20, 2006
No medication is completely safe
Analysis of: Tamiflu to carry warning about abnormal behaviour | www.news-medical.net
Author: GLG Member Program Contributor
Risk of bird flu could become enormous if the virus mutates to allow human to human transmission. Behavioral complications are not at all uncommon with antivirals, e.g. interferon. Medications must always be used with recognition of risk benefit analysis.  
Peter Bornstein Posted November 17, 2006
Uncertainty, not familiarity, breeds contempt
Analysis of: Tamiflu to carry warning about abnormal behaviour | www.news-medical.net
Author: Peter Bornstein, Partner St. Paul Infectious Disease Associates, Ltd
Reports from Japan reveal episodes of psychiatric illness in patients taking Tamiflu (oseltamivir).  As a result, the US Food and Drug Administration (FDA) is recommending patients be closely monitored for these side effects.
Previous Page : 11 12 13 14 15 16 17 18 19 20 21 22 23 Next201 to 210 of 227

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T05:45:18.353